Peptides and combination of peptides for use in immunotherapy against Hepatocellular carcinoma (HCC) and other cancers

Patent metadata

Field	Value
Publication number	US-11786583-B2
Application number	US-202117245918-A
Country	US
Kind code	B2
Filing date	Apr 30, 2021
Priority date	Dec 23, 2014
Publication date	Oct 17, 2023
Grant date	Oct 17, 2023

Abstract

A peptide consists of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6), an adjuvant, and a pharmaceutically acceptable carrier.

First claim

The invention claimed is:

1. A peptide consisting of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6) in the form of a pharmaceutically acceptable salt.

2. The peptide of claim 1 , wherein said peptide has the ability to bind to a major histocompatibility complex (MHC) class-I molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD8+ T cells.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

4. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

5. The peptide in the form of a pharmaceutically acceptable salt of claim 1 , wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

6. A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises a buffer.

7. A composition comprising the peptide of claim 1 , wherein the composition comprises an adjuvant and a pharmaceutically acceptable carrier.

8. The composition of claim 7 , wherein the peptide is in the form of a chloride salt.

9. The composition of claim 7 , wherein the peptide is in the form of an acetate salt.

10. The composition of claim 7 wherein the adjuvant is selected from the group consisting of imiquimod, resiquimod, granulocyte-macrophage colony-stimulating factor (GM-CSF), cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, polyinosinic:polycytidylic acid (poly-(I:C)), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

11. The composition of claim 10 , wherein the adjuvant is IL-2.

12. The composition of claim 10 , wherein the adjuvant is IL-7.

13. The composition of claim 10 , wherein the adjuvant is IL-12.

14. The composition of claim 10 , wherein the adjuvant is IL-15.

15. The composition of claim 10 , wherein the adjuvant is IL-21.

16. A pegylated peptide consisting of the amino acid sequence of KLSPTVVGL (SEQ ID NO: 6) or a pharmaceutically acceptable salt thereof, wherein the peptide is cross-linked with a polyethylene glycol (PEG).

17. The peptide of claim 16 , wherein the pharmaceutically acceptable salt is chloride salt.

18. The peptide of claim 16 , wherein the pharmaceutically acceptable salt is acetate salt.

19. A composition comprising the pegylated peptide of claim 16 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20. A peptide consisting of the amino acid sequence of KLSPTVVGL (SEQ ID NO: 6), wherein at least one amino acid of the peptide is a D-amino acid.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Weinschenk Toni
• Mahr Andrea
• Fritsche Jens
• Mueller Phillip
• Wiebe Anita
• Kutscher Sarah

Classifications

• A61K2039/5158

  Antigen-pulsed cells, e.g. T-cells · CPC title

• A61K2039/5154

  Antigen presenting cells [APCs], e.g. dendritic cells or macrophages · CPC title

• C12N15/115

  Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} · CPC title

• C12N5/0636

  T lymphocytes · CPC title

• A61K35/17 Primary

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title